Loading clinical trials...

A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

NCT00747734•Genentech, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. This study will be conducted at up to three study centers in the United States.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18 years
•Incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior regimen
•Evaluable or measurable disease per RECIST (in certain circumstances, prostate or ovarian cancer patients with non-measurable disease)

Exclusion Criteria

•Inadequate hematologic or organ function
•Anti-cancer therapy within 4 weeks prior to initiation of study treatment
•Recent history of or current clinically significant gastrointestinal, cardiovascular or pulmonary disorders
•Any condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytics, or a filter of the inferior vena cava
•Active infection or autoimmune disease
•Known human immunodeficiency virus (HIV) infection
•Pregnancy or breast feeding

Key Dates

Start Date

September 1, 2008

Last Updated

April 20, 2011

Enrollment

ACTUAL participants

Conditions

Solid Cancers

Interventions

MNRP1685A

DRUG

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842

Advanced Solid Cancers

View study

RECRUITINGNA

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

NCT03514368

Solid Cancers

View study

RECRUITINGPHASE1/PHASE2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Real-life Performance Evaluation of the LiFlow X-ray Platform

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers